retatrutide type 2 diabetes phase 2 results 2024 2025 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released trial demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide just delivered one of
Description
The question is what else is going with it
If necessary, they may adjust your Wegovy treatment plan
Liraglutide also alleviated SAH-induced early brain injury and inflammation
Phase 2 data focused on metabolic outcomes, and GLP-1 receptor activity in mood-regulating brain regions remains a theoretical rather than proven concern
